TY - JOUR
T1 - Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma
AU - Gordon, Max J.
AU - Duan, Zhigang
AU - Zhao, Hui
AU - Nastoupil, Loretta
AU - Ng, Samuel
AU - Danilov, Alexey V.
AU - Iyer, Swaminathan
AU - Giordano, Sharon H.
N1 - Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - We conducted a population-based study of patients >65 years, diagnosed 2008-2017, with peripheral T-cell lymphoma (PTCL) using SEER-Medicare. Associations between PTCL subtype, treatment regimen, comorbidity, and mortality were assessed using the Kaplan-Meier method and multivariable Cox regression. Amongst the 2,546 patients, the median age was 77 years (interquartile range, 71–83). 5-year overall survival (OS) ranged from 22.2% to 37.3% depending on PTCL subtype. The most common frontline regimen was cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). 5-year OS rate was 47.0% for patients treated with etoposide + CHOP (N = 67; CHOEP), 33.7% for those treated with CHOP (N = 732), and 23.8% for patients treated with non-anthracycline-containing regimens (N = 105; p < 0.001). In patients without comorbidities, CHOEP remained independently associated with improved OS (HR 0.52, 95% CI,0.30-0.91). Median OS was 1.2 years from initiation of second-line therapy (N = 228) independent of treatment regimen. Frontline but not second-line treatment regimen is associated with OS in older patients with PTCL.
AB - We conducted a population-based study of patients >65 years, diagnosed 2008-2017, with peripheral T-cell lymphoma (PTCL) using SEER-Medicare. Associations between PTCL subtype, treatment regimen, comorbidity, and mortality were assessed using the Kaplan-Meier method and multivariable Cox regression. Amongst the 2,546 patients, the median age was 77 years (interquartile range, 71–83). 5-year overall survival (OS) ranged from 22.2% to 37.3% depending on PTCL subtype. The most common frontline regimen was cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). 5-year OS rate was 47.0% for patients treated with etoposide + CHOP (N = 67; CHOEP), 33.7% for those treated with CHOP (N = 732), and 23.8% for patients treated with non-anthracycline-containing regimens (N = 105; p < 0.001). In patients without comorbidities, CHOEP remained independently associated with improved OS (HR 0.52, 95% CI,0.30-0.91). Median OS was 1.2 years from initiation of second-line therapy (N = 228) independent of treatment regimen. Frontline but not second-line treatment regimen is associated with OS in older patients with PTCL.
KW - Comorbidity
KW - Geriatric oncology
KW - Peripheral T-cell lymphoma (PTCL)
KW - Stem cell transplant
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85170834592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85170834592&partnerID=8YFLogxK
U2 - 10.1080/10428194.2023.2256908
DO - 10.1080/10428194.2023.2256908
M3 - Article
C2 - 37706491
AN - SCOPUS:85170834592
SN - 1042-8194
VL - 64
SP - 2258
EP - 2268
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 14
ER -